Hutchinson's CEO Discusses F3Q2012 Results - Earnings Call Transcript

Hutchinson Technology Inc. (HTCH)

F3Q2012 Results Earnings Call

July 26, 2012 5:00 PM ET

Executives

Chuck Ives – Treasurer and Director, Investor Relations

Wayne Fortun – Chief Executive Officer

Rick Penn – President, Disk Drive Components Division

Dave Radloff – Chief Financial Officer

Analysts

Sherri Scribner – Deutsche Bank

Presentation

Operator

Compare to:
Previous Statements by HTCH
» Hutchinson Technology's CEO Discusses F2Q12 Results - Earnings Call Transcript
» Hutchinson Technology CEO Discusses F1Q2012 Results - Earnings Call Transcript
» Hutchinson Technology CEO Discusses F4Q2011 Results - Earnings Call Transcript
» Hutchinson Technology Inc CEO Discusses F3Q11 Results - Earnings Call Transcript

Good day, ladies and gentlemen. Thank you for standing by. Welcome to the Hutchinson Technology Third Quarter Results Conference Call. During today's presentation, all parties will be in a listen-only mode. Following the presentation, the conference will be open for questions. (Operator Instructions)

This conference is being recorded today, Thursday, June 26, 2012. I would now like to turn the conference over to Mr. Chuck Ives, Treasurer and Director of Investor Relations. Please go ahead, sir.

Chuck Ives

Good afternoon, everyone. Welcome to our third quarter results conference call. On the call with me today are Wayne Fortun, our Chief Executive Officer; Rick Penn, President of our Disk Drive Components Division; and Dave Radloff, our Chief Financial Officer.

Wayne will provide an overview of the business; Rick will provide an update on our Disk Drive Components Division and Dave will speak to our financial results and guidance.

As a reminder, we will be providing forward-looking information on demand for and shipments of disk drives and the company's products, ramping new programs, product mix, pricing, production capabilities and volumes, the restoration of our assembly operation in Thailand, capital spending, product costs, operating expenses, product commercialization and adoption, clinical study results and the company's cost structure, operating performance and financial results.

1 2 3 Next › Last »